Lynch Ryan C, Binkley Michael Sargent
Division of Hematology/Oncology, University of Washington, Seattle, WA.
Department of Radiation Oncology, Stanford University, Stanford, CA.
Semin Radiat Oncol. 2025 Jan;35(1):40-46. doi: 10.1016/j.semradonc.2024.11.002.
Immune checkpoint inhibitors have transformed the future management of classic Hodgkin lymphoma (CHL) in the frontline and salvage settings. Both nivolumab and pembrolizumab have high efficacy in CHL allowing for reduction of chemotherapy and possibly the use of radiotherapy based on short-term follow-up. In this review article, we highlight recent trials enrolling patients with relapse and refractory classic Hodgkin lymphoma receiving monotherapy with PD-1 inhibitors as well as PD-1 and chemotherapy regimens. We also highlight frontline trials utilizing PD-1 inhibitors with chemotherapy with or without radiotherapy. Collectively, the role for radiotherapy in the frontline or salvage setting will become more defined with long-term follow-up of completed studies and results generated from future studies.
免疫检查点抑制剂已经改变了经典型霍奇金淋巴瘤（CHL）一线和挽救治疗的未来管理模式。纳武单抗和派姆单抗在CHL中均具有高效性，基于短期随访结果，可减少化疗次数，甚至可能减少放疗的使用。在这篇综述文章中，我们重点介绍了近期针对复发和难治性经典型霍奇金淋巴瘤患者进行的试验，这些试验涉及接受PD-1抑制剂单药治疗以及PD-1与化疗联合方案治疗的患者。我们还重点介绍了在一线治疗中使用PD-1抑制剂联合化疗（无论是否联合放疗）的试验。随着已完成研究的长期随访以及未来研究结果的产生，放疗在一线或挽救治疗中的作用将变得更加明确。
